English
|
Spanish
Supporting oncology professionals through education
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Our founders
Funding statement
Contact us
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
Costs of licensing clinical trials
Share :
ECCO 15 - ESMO 34
20 - 24 Sep 2009
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
3 Nov 2009
Views:
10276
Rating:
Save
Rate video
Prof. John Smyth - Assistant Principal Cancer Research Development, University of Edinburgh
Discusses the issue of the cost of licensing trials with managing editor Professor Gordon McVie, at ECCO 15 - ESMO 34, Berlin, 2009.
Categories:
Drug development
Related Videos
The combination of regorafenib, nivolumab and SCRT shows promising efficacy as...
Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium
25 Jul 2024
Preview: World Cancer Congress 2024
Union for International Cancer Control
17 Jul 2024
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful...
Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea
15 Jul 2024
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...
12 Jul 2024
Research highlights in gastrointestinal tumours
Dr Jesus Fabregas - Memorial Cancer Institute, Miami, USA
12 Jul 2024
GIST tumours and soft tissue sarcomas
Dr Atif Hussein - Memorial Cancer Institute, Miami, USA
12 Jul 2024
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA
12 Jul 2024
Antibody drug conjugates coming to primetime and new agents for breast cancer
Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA
12 Jul 2024
Intervention of osteoclastogenesis that occurs in breast cancer and multiple...
Dr Gregg Fields - Florida Atlantic University, Florida, USA
12 Jul 2024
More from
e
cancer